22Nov
News
Addressing the challenges facing SMEs in climate action
The facilities, located on the Alava Technology Park, include state-of-the-art technology to develop drugs and provide support to the business sector
The European pharmaceutical market foresees turnover of 260 billion euros in 2022, with an annual increase of 3.2%. By then, according to the consultancy firm Evaluate, the national market will represent at least 16.9 billion euros and will be the fifth most important country in the sector in Europe, where it is worth highlighting the leading position of the Basque Country, which has an optimum healthcare, technological and educational sector to drive the pharmaceutical industry at an international level.
Such is the case of the TECNALIA research and technological development centre and the University of the Basque Country that today, with the promotion and support of the Provincial Council of Alava; they have opened the first laboratory 4.0 in the Basque Country for the pharmaceutical industry, located on the Alava Technology Park. The event was presided by the President of the Basque Country, Iñigo Urkullu, the Deputy General of Alava, Ramiro González; the rector of the UPV/EHU, Nekane Balluerka, and the Chairman of TECNALIA, Emiliano López Atxurra.
